Clinical Trial Update: A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation. [Phase 3]

View source ↗

Summary

A multicenter Phase 3 trial assessed the efficacy, safety, and tolerability of the fixed-dose combination indacaterol maleate and glycopyrronium bromide in COPD…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Indacaterol maleate / glycopyrronium bromide

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED | Results posted: 2015-06-09